強直性脊椎炎(ベクテレフ病):治療薬開発パイプライン動向(2016年下半期版)

【英語タイトル】Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016

Global Markets Directが出版した調査資料(DATA70209232)・商品コード:DATA70209232
・発行会社(調査会社):Global Markets Direct
・発行日:2016年11月16日
・ページ数:163
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における強直性脊椎炎(ベクテレフ病)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・強直性脊椎炎(ベクテレフ病)の概要
・強直性脊椎炎(ベクテレフ病)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・強直性脊椎炎(ベクテレフ病)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・強直性脊椎炎(ベクテレフ病)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・強直性脊椎炎(ベクテレフ病)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis – Pipeline Review, H2 2016, provides an overview of the Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine’s bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 2, 7, 2, 13, 6 and 2 respectively.Ankylosing Spondylitis.

Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ankylosing Spondylitis (Bekhterev’s Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Ankylosing Spondylitis (Bekhterev’s Disease) – Overview 9
Ankylosing Spondylitis (Bekhterev’s Disease) – Therapeutics under Development by Companies 10
Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Ankylosing Spondylitis (Bekhterev’s Disease) – Products under Development by Companies 16
Ankylosing Spondylitis (Bekhterev’s Disease) – Companies Involved in Therapeutics Development 19
AbbVie Inc 19
Alteogen Inc. 20
Amgen Inc. 21
BIOCAD 22
Biocon Limited 23
Bionovis SA 24
Brickell Biotech, Inc. 25
Celgene Corporation 26
Coherus BioSciences, Inc. 27
Genor BioPharma Co Ltd 28
Innovent Biologics, Inc. 29
Johnson & Johnson 30
Momenta Pharmaceuticals, Inc. 31
Mycenax Biotech Inc. 32
NeuClone Pty Ltd 33
Novartis AG 34
Oncobiologics, Inc. 35
Panacea Biotec Limited 36
Protalix BioTherapeutics, Inc. 37
Reliance Life Sciences Pvt. Ltd. 38
Sandoz International GmbH 39
Shanghai Pharmaceutical Co., Ltd. 40
Therapeutic Proteins International, LLC 41
Vitae Pharmaceuticals, Inc. 42
Xbrane Biopharma AB 43
Ankylosing Spondylitis (Bekhterev’s Disease) – Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
adalimumab biosimilar – Drug Profile 53
adalimumab biosimilar – Drug Profile 55
adalimumab biosimilar – Drug Profile 56
adalimumab biosimilar – Drug Profile 57
adalimumab biosimilar – Drug Profile 58
adalimumab biosimilar – Drug Profile 59
adalimumab biosimilar – Drug Profile 60
adalimumab biosimilar – Drug Profile 62
adalimumab biosimilar – Drug Profile 64
adalimumab biosimilar – Drug Profile 65
adalimumab biosimilar – Drug Profile 66
adalimumab biosimilar – Drug Profile 67
adalimumab biosimilar – Drug Profile 68
adalimumab biosimilar – Drug Profile 69
apremilast – Drug Profile 70
BBI-6000 – Drug Profile 81
certolizumab pegol biosimilar – Drug Profile 83
DNX-114 – Drug Profile 84
DNX-514 – Drug Profile 85
etanercept biosimilar – Drug Profile 86
etanercept biosimilar – Drug Profile 87
etanercept biosimilar – Drug Profile 89
etanercept biosimilar – Drug Profile 90
etanercept biosimilar – Drug Profile 91
etanercept biosimilar – Drug Profile 92
etanercept biosimilar – Drug Profile 93
etanercept biosimilar – Drug Profile 96
etanercept biosimilar – Drug Profile 97
golimumab – Drug Profile 99
golimumab biosimilar – Drug Profile 107
golimumab biosimilar – Drug Profile 108
infliximab biosimilar – Drug Profile 109
infliximab biosimilar – Drug Profile 110
infliximab biosimilar – Drug Profile 111
infliximab biosimilar – Drug Profile 114
infliximab biosimilar – Drug Profile 115
infliximab biosimilar – Drug Profile 118
infliximab biosimilar – Drug Profile 119
infliximab biosimilar – Drug Profile 120
INV-17 – Drug Profile 121
risankizumab – Drug Profile 122
secukinumab – Drug Profile 125
thalidomide – Drug Profile 138
upadacitinib tartrate – Drug Profile 139
VTP-43742 – Drug Profile 141
Ankylosing Spondylitis (Bekhterev’s Disease) – Dormant Projects 143
Ankylosing Spondylitis (Bekhterev’s Disease) – Discontinued Products 145
Ankylosing Spondylitis (Bekhterev’s Disease) – Product Development Milestones 146
Featured News & Press Releases 146
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160

List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Development by Companies, H2 2016 (Contd..2) 21
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H2 2016 22
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alteogen Inc., H2 2016 23
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H2 2016 24
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BIOCAD, H2 2016 25
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H2 2016 26
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bionovis SA, H2 2016 27
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Brickell Biotech, Inc., H2 2016 28
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H2 2016 29
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Coherus BioSciences, Inc., H2 2016 30
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co Ltd, H2 2016 31
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H2 2016 32
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H2 2016 33
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 34
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc., H2 2016 35
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by NeuClone Pty Ltd, H2 2016 36
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2016 37
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics, Inc., H2 2016 38
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H2 2016 39
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 40
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016 41
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H2 2016 42
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2016 43
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Therapeutic Proteins International, LLC, H2 2016 44
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 45
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H2 2016 46
Assessment by Monotherapy Products, H2 2016 47
Number of Products by Stage and Target, H2 2016 49
Number of Products by Stage and Mechanism of Action, H2 2016 51
Number of Products by Stage and Route of Administration, H2 2016 53
Number of Products by Stage and Molecule Type, H2 2016 55
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2016 146
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects (Contd..1), H2 2016 147
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2016 148

List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 47
Number of Products by Targets, H2 2016 48
Number of Products by Stage and Targets, H2 2016 48
Number of Products by Mechanism of Actions, H2 2016 50
Number of Products by Stage and Mechanism of Actions, H2 2016 50
Number of Products by Routes of Administration, H2 2016 52
Number of Products by Stage and Routes of Administration, H2 2016 52
Number of Products by Molecule Types, H2 2016 54
Number of Products by Stage and Molecule Types, H2 2016 54

【レポートのキーワード】

強直性脊椎炎(ベクテレフ病)

★調査レポート[強直性脊椎炎(ベクテレフ病):治療薬開発パイプライン動向(2016年下半期版)] (コード:DATA70209232)販売に関する免責事項を必ずご確認ください。
★調査レポート[強直性脊椎炎(ベクテレフ病):治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆